Mithra Pharmaceuticals Sa Stock Net Income
| MITPFDelisted Stock | USD 6.75 0.00 0.00% |
Fundamental analysis of Mithra Pharmaceuticals allows traders to better anticipate movements in Mithra Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Mithra |
Mithra Pharmaceuticals SA Company Net Income Analysis
Mithra Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Mithra Pharmaceuticals Net Income | (116.88 M) |
Most of Mithra Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mithra Pharmaceuticals SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Mithra Pharmaceuticals SA reported net income of (116.88 Million). This is 134.25% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 120.47% higher than that of the company.
Mithra Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mithra Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mithra Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Mithra Pharmaceuticals by comparing valuation metrics of similar companies.Mithra Pharmaceuticals is currently under evaluation in net income category among its peers.
Mithra Fundamentals
| Return On Equity | -1.39 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (3.60) % | |||
| Current Valuation | 425.3 M | |||
| Shares Outstanding | 56.31 M | |||
| Shares Owned By Insiders | 32.32 % | |||
| Shares Owned By Institutions | 15.87 % | |||
| Price To Book | 9.76 X | |||
| Price To Sales | 17.08 X | |||
| Revenue | 22.67 M | |||
| Gross Profit | 6.94 M | |||
| EBITDA | (101.58 M) | |||
| Net Income | (116.88 M) | |||
| Cash And Equivalents | 29.3 M | |||
| Cash Per Share | 0.59 X | |||
| Total Debt | 125.24 M | |||
| Debt To Equity | 9.62 % | |||
| Current Ratio | 0.80 X | |||
| Book Value Per Share | 0.72 X | |||
| Cash Flow From Operations | (74.39 M) | |||
| Earnings Per Share | (2.82) X | |||
| Number Of Employees | 300 | |||
| Beta | 0.49 | |||
| Market Capitalization | 380.13 M | |||
| Total Asset | 421.92 M | |||
| Z Score | 1.8 | |||
| Net Asset | 421.92 M |
About Mithra Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mithra Pharmaceuticals SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mithra Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mithra Pharmaceuticals SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Mithra Pink Sheet
If you are still planning to invest in Mithra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mithra Pharmaceuticals' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |